Annual Financials for Sanofi
Fiscal year is February-January. All values EUR millions. |
2022 | 2021 | 2020 | 2019 | 2018 |
5-year trend |
Sales/Revenue
|
43B | 37.76B | 36.04B | 36.13B | 34.46B | |
Sales Growth |
- | -12.18% | -4.55% | 0.24% | -4.60% | |
Cost of Goods Sold (COGS) incl. D&A |
15.86B | 13.95B | 13.94B | 14.27B | 13.72B | |
COGS excluding D&A |
- | - | 10.67B | - | - | |
Depreciation & Amortization Expense |
- | - | 3.27B | - | - | |
Depreciation |
- | - | 1.45B | - | - | |
Amortization of Intangibles |
- | - | 1.82B | - | - | |
COGS Growth |
- | -12.03% | -0.02% | 2.34% | -3.83% | |
Gross Income |
27.14B | 23.81B | 22.1B | 21.86B | 20.74B | |
Gross Income Growth |
- | -12.26% | -7.21% | -1.09% | -5.11% | |
Gross Profit Margin |
- | - | - | - | 60.18% | NA |
|
2022 | 2021 | 2020 | 2019 | 2018 |
5-year trend |
SG&A Expense |
17.12B | 15.15B | 14.83B | 15.78B | 15.66B | |
Research & Development |
- | - | 5.53B | - | - | |
Other SG&A |
10.41B | 9.46B | 9.3B | 9.77B | 9.77B | |
SGA Growth |
- | -11.50% | -2.07% | 6.42% | -0.77% | |
Other Operating Expense |
(4M) | - | (4M) | (6M) | (3M) | |
Unusual Expense |
798M | 832M | 1.14B | 4.19B | 2.23B | |
EBIT after Unusual Expense |
9.23B | 7.84B | (1.14B) | 1.89B | 2.85B | |
Non Operating Income/Expense |
- | - | 8.07B | - | - | |
Non-Operating Interest Income |
- | - | 37M | - | - | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
394M | 362M | 463M | 544M | 471M | |
Interest Expense Growth |
- | -8.12% | 27.90% | 17.49% | -13.42% | |
Gross Interest Expense |
- | - | 474M | - | - | |
Interest Capitalized |
- | - | 11M | - | - | |
Pretax Income |
10.42B | 7.8B | 13.78B | 2.82B | 4.41B | |
Pretax Income Growth |
- | -25.18% | 76.69% | -79.52% | 56.09% | |
Pretax Margin |
- | - | - | - | 12.78% | NA |
Income Tax |
2.01B | 1.56B | 1.81B | 139M | 481M | |
Income Tax - Current Domestic |
- | - | 1.91B | - | - | |
Income Tax - Current Foreign |
- | - | - | - | - | |
Income Tax - Deferred Domestic |
- | - | (106M) | - | - | |
Income Tax - Deferred Foreign |
- | - | - | - | - | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
68M | 39M | 359M | 255M | 499M | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
8.48B | 6.28B | 12.33B | 2.94B | 4.42B | |
Minority Interest Expense |
113M | 56M | 36M | 31M | 104M | |
Net Income |
8.37B | 6.22B | 12.29B | 2.91B | 4.32B | |
Net Income Growth |
- | -25.66% | 97.56% | -76.35% | 48.57% | |
Net Margin Growth |
- | - | - | - | 12.53% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | (101M) | (13M) | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
8.37B | 6.22B | 12.29B | 2.81B | 4.31B | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
8.37B | 6.22B | 12.29B | 2.91B | 4.32B | |
EPS (Basic) |
6.69 | 4.97 | 9.81 | 2.33 | 3.46 | |
EPS (Basic) Growth |
- | -25.69% | 97.38% | -76.28% | 48.90% | |
Basic Shares Outstanding |
1.25B | 1.25B | 1.25B | 1.25B | 1.25B | |
EPS (Diluted) |
6.66 | 4.95 | 9.76 | 2.31 | 3.44 | |
EPS (Diluted) Growth |
- | -25.72% | 97.21% | -76.30% | 48.80% | |
Diluted Shares Outstanding |
1.26B | 1.26B | 1.26B | 1.26B | 1.26B | |
EBITDA |
13.73B | 11.8B | 10.54B | 9.82B | 8.55B | |
EBITDA Growth |
- | -14.06% | -10.66% | -6.81% | -13.01% | |
EBITDA Margin |
- | - | - | - | 24.79% | NA |